Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAPT Therapeutics, Inc. (Nasdaq: RAPT) SEC filings page on Stock Titan provides access to the company’s official reports and disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage immunology-based biopharmaceutical company focused on inflammatory and immunological diseases, RAPT uses SEC filings to report financial results, capital-raising activities and other material corporate events.
Investors can review current and historical Form 8-K filings in which RAPT reports items such as quarterly and year-to-date financial results, underwritten public offerings of common stock, and changes to its board of directors and governance arrangements. For example, recent 8-K filings have furnished press releases detailing net losses, research and development and general and administrative expenses, cash and marketable securities balances, and the terms and expected proceeds of a public equity offering intended to fund operations into 2028 based on the company’s stated operating plans.
Beyond 8-Ks, RAPT’s broader SEC reporting (such as Forms 10-Q and 10-K, referenced in its press releases) contains more extensive discussions of risk factors, pipeline programs, clinical trial status and accounting policies. These periodic reports are important for understanding how the company describes its clinical-stage immunology-based business model, including programs like ozureprubart and other early-stage assets, as well as its assessment of capital needs and potential risks.
On Stock Titan, SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as changes in operating expenses, financing transactions, and material clinical or regulatory disclosures described in attached press releases or narrative sections. Users can quickly scan these summaries before diving into the full text of a filing.
For those tracking executive and director matters, RAPT’s filings also include information on board appointments, committee assignments and compensation policies, as seen in governance-related 8-K disclosures. Together, these documents provide a structured record of how RAPT communicates its financial condition, capital structure and development progress to regulators and the market.
RTW Investments, LP and Roderick Wong, M.D. reported beneficial ownership of RAPT Therapeutics, Inc. common stock totaling 1,637,165 shares, representing 5.9% of the class. The holdings relate to shares directly held by certain RTW funds advised by RTW Investments.
The ownership percentages are based on 27,710,871 RAPT shares outstanding as of November 3, 2025, as disclosed in the company’s Form 10-Q. Both RTW Investments and Dr. Wong report shared voting and dispositive power over the 1,637,165 shares and no sole voting or dispositive power.
The filers state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of RAPT Therapeutics.
RAPT Therapeutics, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 110,448 shares of common stock, representing 0.40% of the class as of December 31, 2025.
The reporting persons have shared voting and dispositive power over all 110,448 shares and no sole power. The percentage is based on 27,710,871 shares outstanding as of November 3, 2025, as disclosed in the issuer’s Form 10-Q. They certify the holdings are not for the purpose of changing or influencing control of RAPT.
Glazer Capital, LLC and Paul J. Glazer reported beneficial ownership of 1,486,094 shares of RAPT Therapeutics, Inc. common stock, representing 5.36% of the outstanding class.
The shares are held by funds and managed accounts advised by Glazer Capital, with shared voting and dispositive power over all reported shares and no sole authority. The filers state the position is not held to change or influence control of RAPT Therapeutics and is reported on a passive Schedule 13G basis.
RAPT Therapeutics reported an equity grant to director Scott Braunstein. On 01/30/2026, he received 4,956 shares of common stock at a price of $0 per share as a stock-based award, leaving him with 4,956 shares beneficially owned directly.
The award represents the annual grant of restricted stock units (RSUs) under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting.
RAPT Therapeutics director Michael F. Giordano reported a stock-based compensation grant. On 01/30/2026 he received 4,956 shares of common stock at a price of $0, reported as directly owned after the transaction.
The footnote explains this represents the annual grant of restricted stock units under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each unit will deliver one share of common stock upon vesting.
RAPT Therapeutics director Mary Ann Gray received an annual equity grant. On 01/30/2026 she was awarded 4,956 shares of common stock at a grant price of $0, reported as stock under the company’s non-employee director compensation policy.
The award represents 4,956 restricted stock units that fully vest on the first anniversary of the grant date. Each RSU converts into one share of RAPT Therapeutics common stock upon vesting, aligning director compensation with shareholder equity performance.
RAPT Therapeutics director Lori Lyons-Williams reported an annual equity award in the form of restricted stock units. On January 30, 2026, she was granted 4,956 RSUs of RAPT Therapeutics common stock at a price of $0 per unit under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs will fully vest on the first anniversary of the grant date, with each RSU converting into one share of common stock upon vesting. Following this grant, she beneficially owns 4,956 common shares, held directly.
RAPT Therapeutics director Linda Kozick received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a stated price of $0 per unit under the company’s non-employee director compensation policy.
The RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting. Following this grant, Kozick beneficially owns 4,956 shares directly through these RSUs.
RAPT Therapeutics director Ashley L. Dombkowski received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a grant price of $0. These RSUs were issued under RAPT’s Amended & Restated Non-Employee Director Compensation Policy.
The 4,956 RSUs fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of RAPT common stock upon vesting, and all 4,956 shares are reported as directly owned following this grant.
RAPT Therapeutics received an all-cash tender offer at $58.00 per share from Redrose Acquisition Co., a wholly owned GSK subsidiary, to acquire all outstanding common stock via a tender offer followed by a short-form merger under Delaware law. The board unanimously determined the offer and merger consideration are fair and in the best interests of stockholders and recommends that holders tender their shares. As of January 30, 2026, RAPT had 30,922,702 shares outstanding, plus additional shares issuable under options, RSUs and pre-funded warrants, which will be cashed out or converted into cash-based awards based on the $58 price. Executive officers and directors will receive the same per-share price as other investors, and change-in-control arrangements and equity acceleration produce substantial "golden parachute" payouts, including significant cash and equity value for the CEO and other named executives. The merger agreement also provides post-closing indemnification and D&O insurance protections and commits GSK to maintain specified compensation and benefit levels for continuing employees for one year after closing.